Shots:
- DarwinHealth will receive an upfront and eligible to receive as a commercial milestone, as part of the NCTI collaboration
- The focus of the collaboration is to identify NCTs across tumor subtypes for different cancer types by using quantitative systems biology-based algorithms, databases, and technologies and leads to the development of drugs with multi-subtype indications
- Following the NCTs discovery, BMS gets the proprietary information from DarwinHealth in its drug databases, including specific tumor analyses from MRs or MRUMs of distinct tumor subtypes
Click here to read full press release/ article | Ref: PRNewswire | Image: BMS
The post BMS Signs a Research Collaboration with DarwinHealth to Discover Novel Cancer Target Initiative first appeared on PharmaShots.
